首页> 外文OA文献 >High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.
【2h】

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.

机译:非清髓性干细胞移植后巨细胞病毒感染的高发生率:Campath-1H在延迟免疫重建中的潜在作用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nonmyeloablative conditioning is increasingly used for transplantation in a wide range of diseases, but little is known about its impact on the incidence of infections and immune reconstitution. We examined the pattern and outcome of cytomegalovirus (CMV) infections monitored by polymerase chain reaction-based assays and treated preemptively in 101 patients following nonmyeloablative conditioning containing in vivo Campath-1H. Fifty-one patients (50%) had a CMV infection at a median of 27 days after transplantation with a probability of 84.8% in patients at risk of CMV infection. The probability of recurrence of CMV infection before and after 100 days was 53.6% and 46.6%, respectively, and was more common in unrelated donor transplant recipients. All 3 patients who developed CMV disease died of this complication. The 2 patients with late CMV disease had grade III to IV graft-versus-host-disease (GVHD), which occurred de novo in only 4% of patients and in another 10% following donor lymphocyte infusions. The median time to CD4(+) T-cell count more than 200/microL was 9 months in the 48 patients studied. The probabilities of overall survival and nonrelapse mortality at 18 months were 65% and 27.8%, respectively, with no significant difference in survival between CMV-infected and -uninfected patients. The use of Campath-1H appeared to be associated with a low incidence of GVHD but a high incidence of CMV infections and prolonged immune paresis.
机译:非清髓性调理越来越多地用于多种疾病的移植,但对其感染和免疫重建的影响知之甚少。我们检查了通过基于聚合酶链反应的分析监测的巨细胞病毒(CMV)感染的模式和结果,并在包含体内Campath-1H的非清髓性调节后抢先治疗了101例患者。 51名患者(50%)在移植后的中位数为27天时发生了CMV感染,风险为CMV的患者中有84.8%的可能性。 100天之前和之后CMV感染复发的可能性分别为53.6%和46.6%,并且在无关的供体移植受者中更为常见。所有发生CMV疾病的3名患者均死于该并发症。 2例晚期CMV疾病患者的III至IV级移植物抗宿主疾病(GVHD),仅4%的患者从头发生,在输注供体淋巴细胞后又发生10%。在研究的48位患者中,CD4(+)T细胞计数超过200 / microL的中位时间为9个月。在18个月时,总生存率和非复发死亡率分别为65%和27.8%,在CMV感染和未感染的患者之间,生存率无显着差异。使用Campath-1H似乎与GVHD的发生率低但CMV感染的发生率高和免疫麻痹时间长有关。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号